The major strength of our analysis is that this is the first study that investigates the effect of SGLT-2 inhibitors and GLP-1 RAs on cardiovascular and renal events in type 2 DM patients with CKD [53]. The ADA preferably recommends SGLT-2 inhibitors over GLP-1 RAs in CKD patients; [21] our study supports their recommendations, with additional evidence that GLP-1 analogues can be an alternative option. This evidence concerns the gene GLP1R and chronic kidney disease.